iBio

iBio develops and offers product applications of its iBioLaunch™ and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.

iBio, established in 2008 and headquartered in United States, North America., specializes in Early Stage Venture investments across . The organization boasts a portfolio of 1 investments, with an average round size of $7.5M and 1 successful exits. Their recent investments include . The highest investment round they participated in was $30.0M. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.